DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Brian Lian - 3 Eli Lilly - 2 Viking - 2 Eli Lilly's - 2 Eli Lilly's Zepbound - 1 Goldman Sachs - 1 Eli Lilly’s - 1 Brendan Mcdermid - 1
Top related locs:
New York City Branchburg , New Jersey
Top related orgs:
Viking Therapeutics - 3 Viking - 3 Novo Nordisk - 2 Getty Images Biotech - 1 Novo - 1 U.S . Food - 1 Drug Administration - 1 Company - 1

Search resuls for: "Brian Lian"


3 mentions found


☆ Viking Therapeutics stock jumps more than 25% on promising weight loss pill data
  + stars: | 2024-03-26 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Viking Therapeutics shares jumped more than 25% on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year. The study results add to the excitement around the drugmaker's prospects in the budding weight loss drug market. Based on Tuesday's results, Viking plans to start a phase two trial of its weight loss pill later this year. Weight loss for those patients ranged up to 3.6% higher than those who received a placebo. Viking CEO Brian Lian said during a conference call on Tuesday that it's unclear "how durable" the weight loss is.
Persons: Eli Lilly, Viking, Brian Lian Organizations: Viking Therapeutics, Novo Nordisk, Viking
☆ Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
  + stars: | 2024-03-03 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +8 min
In this article VKTX Follow your favorite stocks CREATE FREE ACCOUNTCr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage. It's too early to say whether Viking's drug could have an edge over existing or developing weight loss treatments. The pharmaceutical giant could also launch a slate of other weight loss treatments over the next few years that may have advantages over Zepbound, whether they offer more weight loss or convenience. That could give Viking the commercial and manufacturing capabilities needed to compete in the weight loss drug market.
Persons: Eli Lilly, Eli Lilly's Zepbound, Viking, Goldman Sachs, Eli Lilly’s, Brendan Mcdermid, GLP, Brian Lian, William Blair, Andy Hsieh, Hsieh, Eli Lilly's, Jefferies, Akash Tewari, doesn't, Mike Segar, Lian, William Blair's Hsieh, Oppenheimer, Jay Olson Organizations: Getty Images Biotech, Viking Therapeutics, Novo Nordisk, Reuters, Viking, Novo, U.S . Food, Drug Administration, Company, Deutsche Bank, CNBC Locations: New York City, Branchburg , New Jersey
☆ Viking Therapeutics stock jumps 80% after positive weight loss drug trial results
  + stars: | 2024-02-27 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company's experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade. Separately, the company said it expects to release early-stage trial data on an oral version of its weight loss drug. Viking Therapeutics' drug targets GLP-1 and another hormone called GIP. Those are the same hormones that Eli Lilly's weight loss and diabetes drugs, Zepbound and Mounjaro, target.
Persons: Brian Lian, Eli Lilly's Organizations: Viking Therapeutics, Viking, Food and Drug Administration
0 next >>
Total: 3